Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GrayBug LLC

Delivering drugs to eye compartments, slowly

This article was originally published in Start Up

Executive Summary

Nearly 12 million intravitreal injections for ophthalmic disease were admistered to patients eyes in 2012, and the figure is a testament to the acceptability of the delivery method whose very concept once inspired gasps and doubts; still, meaningful improvements are almost certain to be welcome and reimbursed in the marketplace. GrayBug LLC is betting it can enhance the outcome of drugs injected into the eye by prolonging their release with a polymer-based delivery system that the firm expects to eventually be formulated as nanoparticles – the goal is to extend intervals between ocular medicine dosing to three months or longer, perhaps as long as six months, with reduced inflammatory effects.

You may also be interested in...



Finance Watch: Chinook Debuts With $65m For Precision Kidney Disease Medicines

Private Company Edition: The start-up intends to take multiple drug candidates into the clinic by 2021. Also, Graybug Vision raises an $80m series B and Finch closes a $53m series C.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Spero Therapeutics: Remodeling Antibiotics

Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.

Topics

Related Companies

UsernamePublicRestriction

Register

CO234398

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel